Positions
- Professor
-
Mol & Cell Biology-Sreekumar
糖心视频 of Medicine
Houston, TX, US
- Director, Metabolomics Shared Resource
-
Dan L Duncan Comprehensive Cancer Center
糖心视频 of Medicine
Houston, Texas, United States
Education
- Advanced Training from University Of Michigan
- 01/2003 - Ann Arbor, MI, United States
- Ph.D. from Indian Institute Of Science
- 01/2000 - Bangalore, India
- M.S. from University Of Pune
- 01/1994 - Pune, India
- BS from University of Mysore
- 05/1992 - Mysore, India
Honors & Awards
- Merit Scholarship
- University of Mysore (01/1989 - 12/1991)
- Scholarship
- National Chemical Laboratory (01/1992 - 12/1994)
- Junior and Senior Research Fellowships
- Council for Scientific and Industrial Research, New Delhi (01/1994 - 12/1999)
- Qualified Graduate Aptitude Test in Engineering
- In General Science and Engineering with 97.69 percentile. Secured all India 56th rank
- Indian Institute of Technology, Kharagpur (01/1994)
- Best Poster Award
- 66th Annual conference for Society of Biological Chemists, Visakhapatnam, India (12/1997)
- Post-Doctoral Training Award
- Department of Defense (01/2001 - 12/2004)
- 2nd Place for Abstract
- Awarded a platform presentation as part of the recognition.
- Cancer Research Symposium (10/2004)
- Georgia Cancer Coalition Distinguished Scientist
- Georgia Cancer Coalition (01/2009)
- Emerging Scientist Award
- Medical College of Georgia (01/2010)
- ASCO-NCI-EORTC Travel Award
- 2010 Diagnostic Development Tutorial (10/2010)
- Molecular Cell Biology Departmental Faculty Award for Research Excellence
- 糖心视频 of Medicine (06/2015)
- Challenge Award 2017
- Prostate Cancer Foundation (01/2017)
Professional Interests
- Cancer Biology
- Drug Resistance Mechanisms
- Metabolism
- Signal Transduction
Websites
Selected Publications
-
SK Noonepalle, F Gu, E Lee, J Choi, Q Han, J Kim, M Ouzounova, A Shull, L Pei, P Hsu, R Kolhe, F Shi, J Choi, K Chiou, T Huang, H Korkaya, L Deng, H Xin, S Huang, M Thangaraju, A Sreekumar, S Ambs, S Tang, DH Munn and H Shi. " " Cancer Immunology Research. 2017 Apr 5; 4 : 330-334.
Pubmed PMID: . -
L Tian, A Goldstein, H Wang, HC Lo, IS Kim, T Welte, K Sheng, L Dobrolecki, X Zhang, N Putluri, T Phung, SA Mani, F Stossi, A Sreekumar, MA Mancini, WK Decker, C Zong, MT Lewis, and XHF Zhang. " " Nature. 2017 Apr 13; 544 (7649) : 250-254.
Pubmed PMID: . -
Li Zhang, Jianghua Wang, Yiqun Zhang, Patricia Castro, Arun Sreekumar, Nagireddy Putluri, Nilanjan Guha, Saligrama Deepak, Arunkumar Padmanaban, Chad J. Creighton and Michael Ittmann. " " Cancer Res. 2016 Nov 1; 76 (21) : 6290-6298.
Pubmed PMID: . -
Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, ... Sreekumar A. " " Nat Commun. 2016 May 19; 7 : 11612.
Pubmed PMID: .
Memberships
- Plos One
- Editorial Board (01/2011)
- Ad-Hoc Review
- current unless indicated (01/2011)
- Study Sections
- (01/2011)
- American Association for Cancer Research
- Member (01/2002)
- Member of American Society for Mass Spectrometry
- Member (01/2011)
- American Society of Clinical Oncology
- Active-Allied Member (01/2011 - 12/2012)
- Houston Metabolomics Society
- Steering Committee Member (01/2013)
- Society for Basic Research in Urology Research
- Publication Committee Member
Funding
-
Tumor Metabolomics Core Facility
- (12/01/2016 - 11/30/2021)
- Unrestricted funding from CPRIT (Edwards)
- To establish a cancer metabolomics core facility at 糖心视频 of Medicine. To support
-
The role of mitochondrial heterogeneity in pyruvate flux in prostate cancer progression.
#R21CA205257 - (04/01/2016 - 03/31/2018)
- Grant funding from NCI
- To understand the role of mitochondrial pyruvate transporters in prostate cancer progression.
-
To develop methods to detect metabolites in biofluids with the longer term goal of applying this to studies in the International Space Station
#GA-2014-136 - (05/27/2014 - 05/26/2019)
- Grant funding from CASIS
-
Delineating racially distinct metabolic pathways in triple negative breast cancer
#1 U01 CA179674-01A1 - (09/01/2014 - 08/31/2019)
- Grant funding from NIH
- Aim 1: Validate elevated levels of unsaturated fatty acids and lipids in AA TN BCa. Aim 2: Functionally characterize the pathways leading to accumulation of 2-OHG and arachidonic acid in AA TN BCa using in vitro and in vivo models. Aim 3: Measure the serum levels of metabolites in tryptophan, unsaturated fatty acids (including arachidonic acid) and 2-HG pathway in AA TN BCa.
-
Agilent Mass Spectrometry
- (08/01/2017 - 07/31/2022)
- Center for Excellence
- This grant funds the development of non-invasive metabolic markers in serum/plasma and urine for cancer detection and prognosis.
-
Genetic and metabolic dissection of the camkk alpha signaling axis in prostate cancer
#1 R01 CA184208-01A1 - (01/27/2015 - 12/31/2019)
- Grant funding from NIH
- To study the metabolic pathways regulated by camkk alpha signaling axis in prostate cancer. This grant was scored at 4th percentile and is awaiting funding after the council meeting.
-
SRC-2 driven 鈥渕etabolic switch鈥 in metastatic prostate cancer- prognostic and therapeutic implications.
#RP150451 - (03/01/2015 - 02/28/2018)
- Unrestricted funding from CPRIT
- To define the metabolic alterations associated with SRC2 action in Castrate Resistant Prostate Cancer
-
Metabolomics Initiative
- (04/01/2015 - 03/19/2019)
- Grant funding from Diana Helis Henry Medical Research Foundation
- To establish a lipidomics facility for Cancer Research
-
Elucidating the Role of Xenobiotic Metabolism in Bladder Cancer Progression
#1127430-RSG-15-105-01-CNE - (07/01/2015 - 06/30/2019)
- Grant funding from American Cancer Society (ACS)
- Define stage specific profiles of key xenobiotic metabolites in bladder cancer, define the regulation and function of AOX1 in bladder cancer and develop a prognostic panel of urinary xenobiotic metabolites.
-
糖心视频 of Medicine Cancer Center
#2 P30 CA125123-09 - (07/01/2015 - 06/30/2020)
- Grant funding from NIH/NCI
- The purpose of this shared resource is to provide investigators with cost-effective, state-of-the-art instrumentation and specialized expertise for analysis of metabolomics with the goal to identify novel metabolic biomarkers and pathways with application in prevention, diagnosis and treatment of cancer.
-
Prostate Cancer
- (10/01/2017 - 09/30/2019)
- Grant funding from Prostate Cancer Foundation
- Clinicopathological correlation & molecular signature identification & risk stratification of prostate cancer in African American U.S. Veterans, with & without exposure to battlefield chemicals.
-
Bladder Cancer and Identification of Altered Metabolism
#1 R01 CA220297-01 - (06/05/2017 - 06/04/2022)
- Grant funding from NIH
- Racial disparity in bladder cancer and identification of altered metabolism in African American compare to European bladder cancer.
-
Metabolomic profiling and biologic basis of racial disparity in prostate cancer
#5 U01 CA167234-03 - $248,959.00 (08/01/2012 - 07/31/2017)
- Grant funding from NCI
- Definitively define and compare the PCa metabolome of AA and EA men and uncover the biological mechanism in an ancestry-verified subset of AA and EA prostate cancers. To functionally characterize the race-associated metabolic pathways and evaluate the pathway-associated metabolites in urine specimens from AA and EA men with prostate cancer.
-
Metabolomic profiling to distinguish racially distinct prognostic markers in prostate cancer
#W81XWH-12-1-0130 - $479,388.00 (09/01/2012 - 08/31/2015)
- Grant funding from DOD
- Metabolomic profiling to distinguish racially distinct prognostic markers in prostate cancer Goals: specifically address metabolic profiles associated with low/high Gleason grade prostate cancer in AA and EA men and to develop tissue microarray based enzymatic signatures for low or high risk prostate cancer.
-
To quantify lipids in a randomized fish oil study in prostate cancer patients.
#W81XWH-12-1-0469 - $36,050.00 (08/08/2014 - 07/31/2015)
- Grant funding from DOD
- To use mass spectrometry to quantify lipids in prostate tissues from men enrolled in a randomized fish oil study. Role: Co-Investigator in the application, Principal Investigator at BCM
-
Integrative Metabolomics of Prostate Cancer Progression
#1R01CA133458-01 - $250,000.00 (04/01/2008 - 03/31/2013)
- Grant funding from NIH
-
Proteomic Profiling of Multiple Myeloma Progression
#602005 - $133,054.00 (10/01/2009 - 05/31/2011)
- Grant funding from Multiple Myeloma Research Foundation
-
Integromics with application to prostate cancer progression
#RCA145444A - $133,054.00 (10/01/2009 - 09/30/2011)
- Grant funding from NIH/NCI
- Role: Co-Principal Investigator
-
Metabolomic Markers for Early Detection of Prostate Cancer
#1 R03 CA139489-01 - $50,000.00 (04/01/2009 - 05/31/2011)
- Grant funding from NIH
-
Development of first-generation multiplex metabolomic biomarker panel in serum for diagnosis and prognosis of breast cancer
#KG110818 - $500,000.00 (10/01/2011 - 10/27/2014)
- Grant funding from Susan Komen Foundation
- The objective of this study is to define and validate the metabolic profiles in tissues and serum from various breast cancer patients. This data was used to develop the subsequent grant applications (including the current one) on breast cancer.
-
IDH1 and metabolic changes in Dnmt3a KO HSCs
#DK92883 metabolomics supplement - $100,000.00 (09/15/2013 - 08/31/2014)
- Grant funding from NIDDK
- This is a metabolomic supplement for the associated RO1 to extend the work to study of IDH1 and metabolic changes in Dnmt3a KO HSCs. Role: Co-Investigator
to edit your profile